Neurocrine Biosciences (NBIX) Position Boosted by Columbus Circle Investors

Columbus Circle Investors raised its stake in shares of Neurocrine Biosciences (NASDAQ:NBIX) by 18.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 376,326 shares of the company’s stock after purchasing an additional 57,520 shares during the quarter. Columbus Circle Investors owned 0.42% of Neurocrine Biosciences worth $31,209,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently made changes to their positions in the business. Perceptive Advisors LLC lifted its position in Neurocrine Biosciences by 7.5% during the fourth quarter. Perceptive Advisors LLC now owns 5,151,589 shares of the company’s stock valued at $399,712,000 after purchasing an additional 360,000 shares during the last quarter. TimesSquare Capital Management LLC lifted its position in Neurocrine Biosciences by 0.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 2,370,050 shares of the company’s stock valued at $183,892,000 after purchasing an additional 21,950 shares during the last quarter. Wells Fargo & Company MN lifted its position in Neurocrine Biosciences by 2.1% during the fourth quarter. Wells Fargo & Company MN now owns 965,449 shares of the company’s stock valued at $74,909,000 after purchasing an additional 20,081 shares during the last quarter. First Trust Advisors LP lifted its position in Neurocrine Biosciences by 9.0% during the fourth quarter. First Trust Advisors LP now owns 852,835 shares of the company’s stock valued at $66,171,000 after purchasing an additional 70,150 shares during the last quarter. Finally, Frontier Capital Management Co. LLC lifted its position in Neurocrine Biosciences by 587.3% during the first quarter. Frontier Capital Management Co. LLC now owns 826,272 shares of the company’s stock valued at $68,523,000 after purchasing an additional 706,047 shares during the last quarter.

Several equities research analysts have issued reports on NBIX shares. BidaskClub lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, April 4th. Bank of America lifted their target price on shares of Neurocrine Biosciences from $101.00 to $102.00 and gave the company a “buy” rating in a research report on Tuesday, May 1st. Oppenheimer reiterated a “buy” rating on shares of Neurocrine Biosciences in a research report on Wednesday, March 21st. ValuEngine upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, Cowen reiterated a “buy” rating and set a $100.00 target price on shares of Neurocrine Biosciences in a research report on Monday, May 7th. Thirteen analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $102.77.

Shares of NBIX opened at $92.49 on Friday. The company has a market capitalization of $8.35 billion, a PE ratio of -57.09 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a current ratio of 11.06 and a quick ratio of 11.06. Neurocrine Biosciences has a fifty-two week low of $92.60 and a fifty-two week high of $94.19.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, April 30th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.18). The business had revenue of $71.08 million during the quarter, compared to the consensus estimate of $65.17 million. Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. equities research analysts expect that Neurocrine Biosciences will post -0.24 earnings per share for the current year.

In other news, CEO Kevin Charles Gorman sold 126,832 shares of the business’s stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $80.75, for a total value of $10,241,684.00. Following the completion of the sale, the chief executive officer now directly owns 473,865 shares in the company, valued at approximately $38,264,598.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Corinne H. Nevinny sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, May 7th. The stock was sold at an average price of $83.13, for a total transaction of $415,650.00. Following the completion of the sale, the director now owns 43,283 shares of the company’s stock, valued at $3,598,115.79. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 207,705 shares of company stock valued at $17,485,904. Company insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply